GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Laboratories International Holdings Ltd (FRA:UNJ) » Definitions » PEG Ratio

United Laboratories International Holdings (FRA:UNJ) PEG Ratio : 0.48 (As of Apr. 28, 2024)


View and export this data going back to 2007. Start your Free Trial

What is United Laboratories International Holdings PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, United Laboratories International Holdings's PE Ratio without NRI is 5.39. United Laboratories International Holdings's 5-Year EBITDA growth rate is 11.20%. Therefore, United Laboratories International Holdings's PEG Ratio for today is 0.48.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for United Laboratories International Holdings's PEG Ratio or its related term are showing as below:

FRA:UNJ' s PEG Ratio Range Over the Past 10 Years
Min: 0.25   Med: 2.9   Max: 16.04
Current: 0.52


During the past 13 years, United Laboratories International Holdings's highest PEG Ratio was 16.04. The lowest was 0.25. And the median was 2.90.


FRA:UNJ's PEG Ratio is ranked better than
86.36% of 374 companies
in the Drug Manufacturers industry
Industry Median: 1.655 vs FRA:UNJ: 0.52

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


United Laboratories International Holdings PEG Ratio Historical Data

The historical data trend for United Laboratories International Holdings's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Laboratories International Holdings PEG Ratio Chart

United Laboratories International Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.81 0.71 0.34 0.45 -

United Laboratories International Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 - 0.45 - -

Competitive Comparison of United Laboratories International Holdings's PEG Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Laboratories International Holdings's PEG Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Laboratories International Holdings's PEG Ratio distribution charts can be found below:

* The bar in red indicates where United Laboratories International Holdings's PEG Ratio falls into.



United Laboratories International Holdings PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

United Laboratories International Holdings's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=5.3926701570681/11.20
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


United Laboratories International Holdings  (FRA:UNJ) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


United Laboratories International Holdings PEG Ratio Related Terms

Thank you for viewing the detailed overview of United Laboratories International Holdings's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


United Laboratories International Holdings (FRA:UNJ) Business Description

Traded in Other Exchanges
Address
No. 6 Fuk Wang Street, Yuen Long Industrial Estate, New Territories, Hong Kong, HKG
United Laboratories International Holdings Ltd is a major drug manufacturing company. United Laboratories is organized into three revenue streams, including Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. Most of the company's sales are generated in China, followed by Europe and India.

United Laboratories International Holdings (FRA:UNJ) Headlines

No Headlines